Serum adiponectin and cardiometabolic risk in patients with acute coronary syndromes;Adiponectina sérica e risco cardiometabólico em pacientes com síndromes coronarianas agudas

Arquivos Brasileiros de Cardiologia

Volumn 101, Issue 5, 2013, Pages 399-408

  Oliveira, Gustavo Bernardes de Figueiredo ^a   França, João Ítalo Dias ^a   Piegas, Leopoldo Soares ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

Acute coronary syndrome; Adiponectin; Insulin resistance; Metabolic syndrome X; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ADIPONECTIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LEPTIN; LOW MOLECULAR WEIGHT HEPARIN; TRIACYLGLYCEROL;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; ANGIOCARDIOGRAPHY; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CORONARY ARTERY BYPASS GRAFT; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INSULIN RESISTANCE; ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; RISK ASSESSMENT; STENOSIS; THROMBOSIS;

ACUTE CORONARY SYNDROME; ADIPONECTIN; AGE FACTORS; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; EPIDEMIOLOGIC STUDIES; FEMALE; HOMEOSTASIS; HOSPITALIZATION; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEX FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84890930998     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.5935/abc.20130186     Document Type: Article

References (40)

1. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB. Overweight and obesity as determinants of cardiovascular risk. Arch Intern Med. 2002;162(16):1867-1872.
2. Kannel WB, Cupples LA, Ramaswami R, Stokes J 3rd, Kreger BE, Higgins M. Regional obesity and risk of cardiovascular disease; the Framingham study. J Clin Epidemiol. 1991;44(2):183-190.
3. Obesity: preventing and managing the global epidemic. Report of a World Health Organization. World Health Org Tech Rep Ser. 2000;894:i-xii-i-253.
4. Grundy SM, Brewer HB, Cleeman JI, Smith SC Jr, Lenfant C; American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433-438.
5. Luciano C, Hulford J, Abdullah A, Zarich S. Metabolic syndrome: a major risk factor for acute myocardial infarction in patients < 45 years of age. J Am Coll Cardiol. 2004;43(5 Suppl 1):A249.
6. Rimm EB, Stampfer MJ, Giovannucci E, Ascherio A, Spiegelman D, Colditz GA, et al. Body size and fat distribution as predictors of coronary heart disease among middle-aged and older US men. Am J Epidemiol. 1995;141(12):1117-1127.
7. Lorenzo C, Williams K, Hunt KJ, Hoffner SM. The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care. 2007;30(1):8-13.
8. Yusuf S, Hawken S, Ôunpuu S, Dans T, Avezum A, Lanas F, et al; INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-952.
9. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-1645.
10. Malik S, Wong ND, Franklin SS, Kamath T V, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in united states adults. Circulation. 2004;110(10):1245-1250.
11. Jeppesen J, Hansen T W, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: a population-based study. J Am Coll Cardiol. 2007;49(21):2112-2119.
12. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(2):131-141.
13. Trujillo ME, Scherer PE. Adiponectin - journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. J Intern Med. 2005;257(2):167-175.
14. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, et al; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119(17):2408-2416. Erratum in Circulation. 2009;119(25):e606.
15. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83.
16. Maeda K, Okubo K, Shimomura I, Funahashi T, Matsuzawa Y, Matsubara K, et al. cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 1996;221(2):286-289.
17. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 1999;100(25):2473-2476.
18. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 2001;103(8):1057-1063.
19. Kato H, Kashiwagi H, Shiraga M, Tadokoro S, Kamae T, Ujiie H, et al. Adiponectin acts as an endogenous antithrombotic factor. Arterioscler Throm Vasc Biol. 2006;26(1):224-230.
20. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose- specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Throm Vasc Biol. 2000;20(6):1595-1599.
21. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA. 2004;291(14):1730-1737.
22. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006;114(7):623-629.
23. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, et al; Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol. 2003;23(1):85-89.
24. Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectina with coronary heart disease and mortality. The Rancho Bernardo study. Am J Epidemiol. 2007;165(2):164-174.
25. Kizer JR, Barzilay JI, Kuller LH, Gottdiener JS. Adiponectin and risk of coronary heart disease in older men and women. J Clin Endocrinol Metab. 2008;93(9):3357-3364.
26. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation. 2005;112(12):1756-1762.
27. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006;92(10):1420-1424.
28. Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adiponectin levels and mortality in elderly men with and without cardiovascular disease and heart failure. Arch Intern Med. 2007;167(14):1510-1517.
29. Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J. 2006;27(19):2300-2309.
30. Oliveira E P, Souza ML, Lima MD. Índice HOMA (homeostasis model assessment) na prática clínica: uma revisão. J Bras Patol Med Lab. 2005;41(4):237-243.
31. Matthews DR, Hosker J P, Rudenski AS, Naylor BA, Treacher D F, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412-419.
32. Thygesen K, Alpert JS, White HD; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. J Am Coll Cardiol. 2007;50(22):2173-2195.
33. Hatano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54(5):541-553.
34. Haddad N. Metodologia de estudos em ciências da saúde. São Paulo: Roca; 2004.
35. Hennekens CH, Buring JE. Epidemiology in medicine. Philadelphia: Lippincott Williams & Wilkins; 1987.
36. Lughlin GA, Barrett-Connor E, May S. Sex-specific determinants of serum adiponectina in older adults: the role of endogenous sex hormones. Intl J Obes (Lond). 2007;31(3):457-465.
37. Wolk R, Berger P, Lennon RJ, Brilakis ES, Davison DE, Somers VK. Association between plasma adiponectin levels and unstable coronary syndromes. Eur Heart J. 2007;28(3):292-298.
38. Schnabel R, Messow CM, Lubos E, Espinola-Klein C, Rupprecht HJ, Bickel C, et al. Association of adiponectin with adverse outcome in coronary artery disease patients: results from the AtheroGene study. Eur Heart J. 2008;29(5):649-657.
39. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631-2639.
40. Barseghian A, Gawande D, Bajaj M. Adiponectin and vulnerable atherosclerotic plaques. J Am Coll Cardiol. 2011;57(7):761-770.